Leerink Partners Maintains Outperform on Arcturus Therapeutics, Raises Price Target to $19

Benzinga Newsdesk www.benzinga.com Positive 94.1%

Neg 0% Neu 0% Pos 94.1%

Leerink Partners analyst Lili Nsongo maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Outperform and raises the price target from $13 to $19.